Journal article icon

Journal article

Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response

Abstract:

Recurrent mutations at R140 and R172 in isocitrate dehydrogenase 2 (IDH2) occur in many cancers, including ∼12% of acute myeloid leukemia (AML). In preclinical models these mutations cause accumulation of the oncogenic metabolite R-2-hydroxyglutarate (2-HG) and induce hematopoietic differentiation block. Single-agent enasidenib (AG-221/CC-90007), a selective mutant IDH2 (mIDH2) inhibitor, produced an overall response rate of 40.3% in relapsed/refractory AML (rrAML) patients with mIDH2 in a ph...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Accepted manuscript

Actions


Access Document


Files:
Publisher copy:
10.1182/blood-2017-04-779447

Authors


Amatangelo, MD More by this author
More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
RDM
Subgroup:
RDM Clinical Laboratory Sciences
Expand authors...
More from this funder
Funding agency for:
Quek, L
Expand funders...
Publisher:
American Society of Hematology Publisher's website
Journal:
Blood Journal website
Volume:
130
Issue:
6
Pages:
732-741
Publication date:
2017-08-10
Acceptance date:
2017-05-28
DOI:
EISSN:
1528-0020
ISSN:
0006-4971
Pubs id:
pubs:700685
URN:
uri:fe1cab64-86fd-40ed-9bbe-700d65bd7794
UUID:
uuid:fe1cab64-86fd-40ed-9bbe-700d65bd7794
Local pid:
pubs:700685
Language:
English

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP